MET amplification has been reported with a fairly low frequency ranging from 0% to 7% in IHCC and EHCC, and from 0% to 18% in GBC.6 Activation of MET signaling is involved in tumor angiogenesis, metastatic progression, and acquired resistance to anti-EGFR treatment.7,8 In a study by Hida and colleagues,9 expression of MET was also strongly correlated with tumor location, T category, AJCC stage, and perineural invasion. The gene discussed is MET; the disease is neoplasm.